CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
50.13
-1.87 (-3.60%)
Feb 4, 2026, 3:51 PM EST - Market open
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 19 analysts that cover CRISPR Therapeutics AG stock have a consensus rating of "Buy" and an average price target of $71.95, which forecasts a 43.53% increase in the stock price over the next year. The lowest target is $32 and the highest is $120.
Price Target: $71.95 (+43.53%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 6 | 6 | 7 | 7 | 7 | 7 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 19 | 19 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $86 → $80 | Buy | Maintains | $86 → $80 | +59.59% | Jan 30, 2026 |
| Needham | Needham | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +59.59% | Dec 23, 2025 |
| Citizens | Citizens | Buy Reiterates $86 | Buy | Reiterates | $86 | +71.55% | Dec 23, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $82 → $74 | Strong Buy | Maintains | $82 → $74 | +47.62% | Nov 26, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $87 → $77 | Strong Buy | Maintains | $87 → $77 | +53.60% | Nov 12, 2025 |
Financial Forecast
Revenue This Year
7.76M
from 37.31M
Decreased by -79.21%
Revenue Next Year
114.55M
from 7.76M
Increased by 1,376.73%
EPS This Year
-6.32
from -4.34
EPS Next Year
-4.16
from -6.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 32.6M | 1.6B | ||||
| Avg | 7.8M | 114.6M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -12.8% | 19,933.5% | ||||
| Avg | -79.2% | 1,376.7% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.22 | 2.76 | ||||
| Avg | -6.32 | -4.16 | ||||
| Low | -6.72 | -6.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.